dostęp otwarty
Kariprazyna — lek przeciwpsychotyczny o profilu częściowego agonisty receptorów dopaminowych
Afiliacje- Katedra i Klinika Psychiatrii, Warszawski Uniwersytet Medyczny Zakład Farmakologii, Instytut Psychiatrii i Neurologii w Warszawie
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
kariprazyna, schizofrenia, profil farmakologiczny, dopamina, częściowy agonista
Informacje o artykuleTytuł
Kariprazyna — lek przeciwpsychotyczny o profilu częściowego agonisty receptorów dopaminowych
Czasopismo
Numer
Typ artykułu
Artykuł przeglądowy
Strony
77-81
Opublikowany online
2018-06-27
Wyświetlenia strony
893
Wyświetlenia/pobrania artykułu
2963
Rekord bibliograficzny
Psychiatria 2018;15(2):77-81.
Słowa kluczowe
kariprazyna
schizofrenia
profil farmakologiczny
dopamina
częściowy agonista
Autorzy
Przemysław Bieńkowski
Referencje (20)- Schatzberg A, Nemeroff C. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 2017.
- Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015; 20(2): 93–97.
- Caraci F, Leggio GM, Salomone S, et al. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017; 6: 397.
- Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017; 7(1): 29–41.
- Ye Na, Song Z, Zhang Ao. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. Curr Med Chem. 2014; 21(4): 437–457.
- McCreary AC, Newman-Tancredi A. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. Curr Pharm Des. 2015; 21(26): 3725–3731.
- Muneer A. Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach. Korean J Fam Med. 2016; 37(3): 137–148.
- Krause M, Zhu Y, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017; 27(9): 835–844.
- Misiak B, Bieńkowski P, Samochowiec J. Kariprazyna – nowy lek przeciwpsychotyczny i jego miejsce w leczeniu schizofrenii. Psychiatria Pol. 2017; 83: 1–14.
- Citrome L, Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013; 30(2): 114–126.
- Citrome L. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. Clin Schizophr Relat Psychoses. 2016; 10(2): 109–119.
- Leggio GM, Bucolo C, Platania CB, et al. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016; 165: 164–177.
- Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016; 21(2): 123–127.
- Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017; 32(6): 309–318.
- Garnock-Jones KP. Cariprazine: A Review in Schizophrenia. CNS Drugs. 2017; 31(6): 513–525.
- Scarff JR. Cariprazine for Schizophrenia and Bipolar Disorder. Innov Clin Neurosci. 2016; 13(9-10): 49–52.
- Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014; 13: 1163–1191.
- Lao KSJ, He Y, Wong ICK, et al. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. CNS Drugs. 2016; 30(11): 1043–1054.
- Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13: 757–777.
- Fang F, Sun H, Wang Z, et al. Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management. CNS Drugs. 2016; 30(9): 845–867.
